Glucotrack Announces Repurchase of Series A Warrants
Glucotrack (Nasdaq: GCTK) has announced the successful repurchase of over 90% of its outstanding Series A Warrants from warrant holders on June 30, 2025. The company repurchased approximately 49,700 Series A Warrants using existing cash, with about 4,300 warrants remaining outstanding. The warrants were originally issued as part of a $10M Public Offering in November 2024.
The repurchase is part of Glucotrack's capital formation strategy and demonstrates confidence in its development of a long-term implantable continuous blood glucose monitoring system for diabetes patients. The company's Series B Warrants were previously converted to common stock, as reported in Q1 2025.
Glucotrack (Nasdaq: GCTK) ha annunciato il riacquisto con successo di oltre il 90% dei suoi Warrants di Serie A in circolazione dai detentori di warrant il 30 giugno 2025. L'azienda ha riacquistato circa 49.700 Warrants di Serie A utilizzando liquidità disponibile, lasciando circa 4.300 warrant ancora in circolazione. I warrant erano stati originariamente emessi nell'ambito di un Offerta Pubblica da 10 milioni di dollari nel novembre 2024.
Il riacquisto fa parte della strategia di formazione del capitale di Glucotrack e dimostra la fiducia nello sviluppo di un sistema impiantabile a lungo termine per il monitoraggio continuo della glicemia per pazienti diabetici. I Warrants di Serie B della società erano stati precedentemente convertiti in azioni ordinarie, come riportato nel primo trimestre del 2025.
Glucotrack (Nasdaq: GCTK) ha anunciado la recompra exitosa de más del 90% de sus Warrants Serie A en circulación a los tenedores el 30 de junio de 2025. La compañía recompró aproximadamente 49,700 Warrants Serie A utilizando efectivo disponible, quedando alrededor de 4,300 warrants pendientes. Los warrants fueron emitidos originalmente como parte de una Oferta Pública de 10 millones de dólares en noviembre de 2024.
La recompra forma parte de la estrategia de formación de capital de Glucotrack y demuestra confianza en el desarrollo de un sistema implantable de monitoreo continuo de glucosa en sangre a largo plazo para pacientes con diabetes. Los Warrants Serie B de la compañía fueron convertidos previamente en acciones ordinarias, según se informó en el primer trimestre de 2025.
Glucotrack (나스�: GCTK)� 2025� 6� 30�� 발행� 시리� A 워런트의 90% 이상� 워런� 보유자로부� 성공적으� 재매입했다고 발표했습니다. 회사� 기존 현금� 사용하여 � 49,700개의 시리� A 워런�� 재매입했으며, � 4,300개의 워런�가 아직 남아 있습니다. � 워런트 2024� 11� 1,000� 달러 공모� 일환으로 처음 발행되었습니�.
이번 재매입은 Glucotrack� 자본 형성 전략� 일환이며, 당뇨� 환자� 위한 장기 이식� 연속 혈당 모니터링 시스� 개발� 대� 신뢰� 보여줍니�. 회사� 시리� B 워런트 2025� 1분기� 보통주로 전환� � 있습니다.
Glucotrack (Nasdaq : GCTK) a annoncé le rachat réussi de plus de 90 % de ses bons de souscription de Série A en circulation auprès des détenteurs le 30 juin 2025. La société a racheté environ 49 700 bons de souscription de Série A en utilisant des liquidités existantes, laissant environ 4 300 bons encore en circulation. Ces bons avaient été initialement émis dans le cadre d’une offre publique de 10 millions de dollars en novembre 2024.
Ce rachat fait partie de la stratégie de formation de capital de Glucotrack et témoigne de la confiance dans le développement d’un système implantable de surveillance continue de la glycémie à long terme pour les patients diabétiques. Les bons de souscription de Série B de la société avaient déjà été convertis en actions ordinaires, comme rapporté au premier trimestre 2025.
Glucotrack (Nasdaq: GCTK) hat den erfolgreichen Rückkauf von über 90 % seiner ausstehenden Serie-A-Warrants von den Inhabern am 30. Juni 2025 bekanntgegeben. Das Unternehmen kaufte etwa 49.700 Serie-A-Warrants mit vorhandenen Barmitteln zurück, wobei noch etwa 4.300 Warrants ausstehen. Die Warrants wurden ursprünglich im Rahmen eines 10-Millionen-Dollar-Öffentlichen Angebots im November 2024 ausgegeben.
Der Rückkauf ist Teil der Kapitalbildungsstrategie von Glucotrack und zeigt Vertrauen in die Entwicklung eines langfristig implantierbaren kontinuierlichen Blutzuckermesssystems für Diabetiker. Die Serie-B-Warrants des Unternehmens wurden bereits im ersten Quartal 2025 in Stammaktien umgewandelt.
- None.
- Remaining 4,300 Series A Warrants still outstanding
- Use of cash reserves for warrant repurchase reduces available working capital
Warrant buyback extinguishes warrant liability accounting and share dilution overhang
RUTHERFORD, N.J., July 08, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it has successfully repurchased over
The repurchase was completed as part of the Company’s capital formation strategy and reflects its continued confidence in its product development of a long-term implantable continuous blood glucose monitoring system for people living with diabetes. The Series A Warrants and Series B Warrants were originally issued in connection with the
Under the terms of the transaction, the Company repurchased approximately 49,700 Series A Warrants, funded with existing cash on hand. Following the repurchase, approximately 4,300 Series A Warrants remain outstanding of which majority of these are also expected to be repurchased. The Series B Warrants were previously extinguished in exchange for common stock as reported in the Form 10Q for the period ending March 31, 2025.
“This warrant repurchase represents an important step towards strengthening our capital structure and delivering value to our shareholders,� said Paul Goode, Chief Executive Officer of Glucotrack. “We are pleased to have reached agreements with the holders and believe this action underscores both our financial strength and confidence in our business outlook.�
About Glucotrack, Inc.
Glucotrack, Inc. (Nasdaq: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.
Glucotrack’s Continuous Blood Glucose Monitor is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use.
For more information, please visit . Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “believe�, “expect�, “plan� and “will� are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC�), including its Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the SEC on March 31, 2025.
Contacts:
Investor Relations:
Media:
